CCG-203971

CCG-203971

Stock Code: 3574891
Manufacturer Part No: SML1422-25MG
Order Now for 7 day delivery
£332.89 (exc VAT) per 25MG
Quantity: - +

Biochem/physiol Actions


CCG-203971 is an inhibitor of the Rho/MKL1/SRF transcriptional pathway, which has been shown to play a role in metastasis of melanoma and breast cancer and clinically associated with castration-resistant prostate cancer. CCG-203971 is a second-generation analog of CCG-1423 (SML0987) with an IC50 of 4.2 µM vs 1 µM for CCG-1423, but less cytotoxicity. In mouse studies, CCG-203971 inhibited invasion of PC-3 prostate cancer cells and was well tolerated up to doses of 100 mg/kg IP over 5 days. The Rho/MRTF/SRF pathway has also been shown to be involved in multiple types of solid organ fibrosis. CCG-203971 repressed both matrix-stiffness and TGF-β-mediated fibrogenesis in human colonic myofibroblasts and showed antifibrotic activity in a murine model of skin injury and in pulmonary fibrosis lung fibroblasts.


Packaging


5, 25 mg in glass bottle

Colourwhite to beige
Quality Level100
InChI keyHERLZBNILRVHQN-UHFFFAOYSA-N
InChI1S/C23H21ClN2O3/c24-19-8-10-20(11-9-19)25-22(27)18-6-2-12-26(15-18)23(28)17-5-1-4-16(14-17)21-7-3-13-29-21/h1,3-5,7-11,13-14,18H,2,6,12,15H2,(H,25,27)
ManufacturerSIGMA-ALDRICH
Storage Temp.2-8°C
Formpowder
Assay≥98% (HPLC)

There are no downloads for this product.